BH - Beauty Health gets FDA clearance for microneedling device for acne scarring

2023-08-02 11:15:41 ET

The Beauty Health Company ( BH ) said it has received FDA clearance for its microneedling device SkinStylus for the treatment of facial acne scarring in people age 22 or older.

The device is already cleared to treat surgical or traumatic hypertrophic scarring on the abdomen in adults. Beauty Health acquired the device in February, commenting that the device complimented its lead product, Hydrafacial, which is often used to prep the skin for microneedling.

Wall Street and Seeking Alpha analysts currently rate the stock a buy. The stock's Quant rating, however, is a sell.

Beauty Health is expected to release its Q2 earnings report on Aug. 9.

More on Beauty Health:

The Beauty Health Company: Still Worried About The FY23 Guidance, Reiterate Hold

The Beauty Health Company 2023 Q1 - Results - Earnings Call Presentation

The Beauty Health Company ( NASDAQ: SKIN ) Q1 2023 Earnings Call Transcript

The Beauty Health GAAP EPS of -$0.17 misses by $0.12, revenue of $86.3M misses by $4.07M

For further details see: